ValiRx PLC Broker Option - Fully Subscribed (0505U)
24 Luglio 2020 - 01:38PM
UK Regulatory
TIDMVAL
RNS Number : 0505U
ValiRx PLC
24 July 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Broker Option - Fully Subscribed
London, UK ., 24 July 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company announces that, further to the
announcement made at 3.02pm on 23 July 2020, the Broker Option - a
facility to allow existing shareholders to participate in the
Fundraise on similar terms to the Placing announced, has been fully
subscribed for by existing shareholders of the Company.
The Broker Option has raised GBP300,700 at a price of 7.5 pence
per share through the issue of 4,009,334 new ordinary shares.
In the announcement made at 3.02pm on 23 July 2020 the
shareholding of Gerry Desler, Chief Financial Officer of the
Company, following the Subscription was erroneously stated as
1,941,875 representing 3.6% of the enlarged share capital. The
shareholding following the Subscription should have stated 81,667
representing 0.2% of the enlarged share capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 7073 2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469 0930
Duncan Vasey / Lucy Williams / Eran
Zucker
Notes for Editors
About ValiRx
ValiRx PLC accelerates the development of innovative medicines
that enhance patient experience. We do this by combining
intellectual and financial resources to select, progress and
partner a balanced portfolio of risk-reduced, early-stage
technologies for translation into clinical candidates.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEKKQBNDBKDQOB
(END) Dow Jones Newswires
July 24, 2020 07:38 ET (11:38 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mar 2023 a Mar 2024